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Despite considerable progress over the past two decades in the management of advanced ovarian cancer, the majority of patients
with this type of malignancy still die from their disease, and the search for new and improved first-line and salvage chemotherapy
regimens continues. As part of this work, the antitumour activity and effect on survival of new chemotherapy combinations containing
the novel taxane docetaxel are being explored. Dual therapy with docetaxel plus a camptothecin (a topoisomerase inhibitor) has
shown promise in second-line treatment, and preliminary data indicate good activity of docetaxel in combination with gemcitabine.
Triple-therapy studies have produced mixed results, but encouraging activity has been reported when the anthracycline, epirubicin, is
added to docetaxel and carboplatin – sequential therapy with docetaxel, cisplatin and epirubicin is currently being assessed.
Combinations of docetaxel, carboplatin and gemcitabine may also be of future interest. Early efficacy and tolerability results with
novel combination chemotherapy regimens involving docetaxel thus offer the promise of additional progress in the chemotherapy of
advanced ovarian cancer, and further trials should be encouraged.
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Ongoing developments in the treatment of ovarian cancer,
particularly the adoption of platinum-based chemotherapy and
the subsequent introduction of the taxanes, have ensured that
outcomes in women with this disorder have improved over the last
20 years. However, the majority of patients affected by ovarian
cancer still die from their disease, and researchers continue to seek
new and more effective first-line and salvage therapies (Kaye,
2001a).
As part of these efforts, the novel taxane docetaxel is being
explored as an alternative to paclitaxel as a platinum partner for
chemotherapy in ovarian cancer (for a further review, see article 2,
Katsumata, 2003). Phase II clinical investigations have demon-
strated the activity of second-line docetaxel monotherapy in
patients previously treated with regimens based on paclitaxel
(Verschraegen et al, 2000) or platinum therapy (Kavanagh et al,
1996; Katsumata et al, 2000). In these studies involving a total of
145 assessable patients, objective overall response rates ranged
from 23 to 40% and median overall survival from approximately 10
months to just over 1 year.
It has been suggested that combinations of docetaxel and
carboplatin might produce high response rates and confer
tolerability advantages in women with advanced ovarian cancer
following promising trial findings (Markman et al, 2001; Vasey PA
et al, 2001). Combinations of cisplatin or carboplatin with
paclitaxel are associated with significant peripheral neuropathy,
but early experience with carboplatin plus docetaxel has shown the
predominant toxicities to be haematological, with no neuropathy
of greater severity than grade II (Meyer et al, 1999). Subsequent
Phase II and Phase III results have confirmed these findings
(Markman et al, 2001; Vasey PA et al, 2001), with paclitaxel
showing significantly more neurotoxicity than docetaxel when
either is used in combination with carboplatin (Vasey PA et al,
2001).
Although combinations of taxanes and platinum agents are
associated with good response rates in advanced ovarian cancer,
the search for novel agents and combinations continues. Current
approaches that show potential include the addition of a third
agent to combination chemotherapy, and the substitution of
platinum agents by nonplatinum alternatives in taxane-based
doublets. This article reviews the efficacy and toxicity of these
novel combinations in the treatment of advanced epithelial ovarian
cancer.
DOCETAXEL AND THE CAMPTOTHECINS
The camptothecins constitute a class of antitumour agents with a
unique mechanism of action. These drugs block the activity of
topoisomerase I — a nuclear enzyme that relaxes torsionally
strained DNA — and thereby induce single-strand DNA breaks
and cell death (Moore and Erlichman, 2001). Camptothecin
derivatives in development include irinotecan (CPT-11) and
topotecan, and the difference in the mechanism of action between
these camptothecins and docetaxel suggests the likelihood of
additive cytotoxic effects when they are used in combination.
Docetaxel and CPT-11
CPT-11 has been shown to have activity in ovarian and non-small-
cell and small-cell lung cancer, and in colon cancer refractory to
treatment with 5-fluorouracil (Moore and Erlichman, 2001). Late
Phase II data from Japan showed partial responses in 13 of 55
patients with ovarian cancer, giving a response rate of 23.6%, with
a 23.1% response in 52 pretreated patients (Takeuchi et al, 1991). *Correspondence: Dr JU Ma ¨enpa ¨a ¨; E-mail: johanna.maenpaa@pshp.fi
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tion for recurrent ovarian cancer because the cytotoxic effects of
the two drugs are likely to be additive; in addition, common
toxicities (with the exception of neutropenia and diarrhoea) are
lacking.
The efficacy and tolerability of docetaxel plus CPT-11 were
investigated in a Finnish Phase I study in eight patients who had
failed first-line therapy with regimens based on a platinum agent
and/or paclitaxel (Ma ¨enpa ¨a ¨ et al, 1998). Docetaxel was given as a 1-
h infusion, followed by CPT-11 over 30–60min, every 3 weeks to a
maximum of six treatment cycles. Doses of docetaxel 60mgm
 2
and CPT-11 200mgm
 2 were recommended for Phase II studies
on the basis of the results in this patient population, with dose-
limiting toxicities being neutropenia and diarrhoea. No patient
developed fluid retention. One partial response was reported and
all four patients were evaluable for the cancer antigen 125 (CA
125); a cell surface glycoprotein detectable in 80% of cases of
epithelial ovarian cancer (Beers and Berkow, 1999) showed
reductions (lasting for 3–12 weeks) in levels of this marker.
The Finnish group have followed their Phase I work with a Phase
II study of second-line treatment in 30 patients receiving up to six
cycles of chemotherapy with the regimen suggested above
(Ma ¨enpa ¨a ¨ et al, 1999). The overall response rate was 63% (16.6%
complete response rate), with no difference between chemosensi-
tive or chemoresistant disease. A total of six of 10 patients
previously treated with paclitaxel responded, with a median
duration of response of 6 months. After a median follow-up of
20 months, median progression-free and overall survival were 9
and 14 months, respectively. The main adverse effect was
neutropenia, which was reported in half of all treatment cycles,
although grade IV neutropenia with complications was noted in
only 15% of cycles. Frequencies of grade III–IV neutropenia are
shown by treatment cycle in Figure 1. There were no reports of
anaemia or thrombocytopenia of grade II severity or above.
Overall, these results showed the combination of docetaxel with
CPT-11 to be effective in the second-line treatment of ovarian
cancer. The incidence of neutropenic complications suggests,
however, that direct combination of these agents with carboplatin
as triple therapy is likely to be impractical, and that preferable
options include sequential administration, addition of granulocyte
colony-stimulating factor (G-CSF) and dose reduction.
Based on the promising activity of docetaxel–CPT-11 in
recurrent ovarian cancer, UK and Finnish investigators conducted
a randomised feasibility trial in the first-line setting, where 100
patients were initially given carboplatin AUC7 four cycles followed
by either docetaxel 100mgm
 2 (51 patients) or docetaxel
60mgm
 2 and CPT-11 200mgm
 2 (49 patients) for four
additional cycles. Currently, no response data concerning the last
four cycles are yet available but the main toxicity, neutropenia, was
manageable (Jayson et al, 2003).
Docetaxel and topotecan
Topotecan is a camptothecin derivative with promising activity in
ovarian and small-cell lung cancer (Moore and Erlichman, 2001). A
meta-analysis of data from five multicentre studies (523 patients;
116 with first-line treatment failure), in which topotecan
1.5mgm
 2 daily for 5 days was used, showed an overall response
rate of 37.1% in 35 patients with advanced ovarian cancer
described as sensitive to second-line therapy (relapse more than
6 months after first-line chemotherapy with a platinum agent plus
paclitaxel) (Gore et al, 2000). The median times to progression and
survival were 31.6 and 98.6 weeks, respectively (Table 1). Toxicities
were noncumulative, with myelotoxicity predominating as ex-
pected: grade III and IV neutropenia was observed in 32.5 and
41.5% of courses, respectively, but was generally manageable.
The efficacy and tolerability of docetaxel in combination with
topotecan has been evaluated in a pilot study in 12 patients with
recurrent epithelial cancer of the ovary and peritoneum, all of
whom had received prior chemotherapy based on paclitaxel and a
platinum agent (Aijaz et al, 2000). These patients had a good
Karnofsky performance status at baseline (median 70%) and had
received a median of two cycles of previous chemotherapy.
Docetaxel 80mgm
 2 was given over 1h on day 1 and topotecan
1.0mgm
 2 was administered over 30min daily for 5 days in a 4-
weekly cycle. The G-CSF support was started on day 6 and
continued until recovery of the neutrophil count. One complete
and four partial responses were reported, with stable disease in
four additional patients. Significant palliation of disease symptoms
and improvements in quality of life were noted in responding
patients. Grade III–IV neutropenia was the predominant adverse
effect; other reported toxicities included thrombocytopenia,
asthenia, vomiting, mucositis and paraesthesia. The authors
concluded that the docetaxel/topotecan combination had signifi-
cant clinical activity with acceptable toxicity as a palliative
treatment for recurrent ovarian and peritoneal cancer.
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Figure 1 Frequency of grade III–IV neutropenia in a Finnish Phase II
study of 3-weekly docetaxel 60mgm
 2 plus irinotecan (CPT-11)
200mgm
 2 in the second-line treatment of recurrent ovarian cancer
(Ma ¨enpa ¨a ¨ et al, 2002). All 30 participating patients had received prior
platinum-based chemotherapy, with prior paclitaxel in 10 patients.
Numbers of patients evaluated in each cycle are shown below the cycle
number.
Table 1 Response rates, time to progression and overall survival in patients with advanced ovarian cancer receiving second-line therapy with topotecan
1.5mgm
 2 daily for 5 days (Gore et al, 2000)
Treatment group
No. of patients
evaluable for
clinical response
Overall
response rate
(%)
Complete
response rate
(%)
Median time to
progression
(weeks)
Median overall
survival
(months)
Platinum+paclitaxel-refractory 48 6.3 0 13.4 45.2
Platinum+paclitaxel-resistant
a 33 12.1 0 15.1 45.3
Platinum+paclitaxel-sensitive
b 35 37.1 11.4 31.6 98.6
aRelapse within 6 months of first-line therapy.
bRelapse more than 6 months after first-line therapy.
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Vinorelbine is a semisynthetic alkaloid derived from the periwin-
kle Vinca rosea. Like other vinca alkaloids (which include
vincristine, vinblastine and vindesine), vinorelbine is a spindle
poison that arrests mitosis through alteration of microtubular
proteins (Beers and Berkow, 1999).
The activity of vinorelbine in advanced epithelial ovarian cancer
has been shown by Phase II data obtained in 38 women with
persistent or recurrent disease who had received prior platinum-
based chemotherapy (Burger et al, 1999). A total of 11 objective
tumour responses (four complete) were reported, with a median
duration of response of 19 weeks and median survival of 60 weeks.
In total of four of 12 patients with platinum-resistant disease
responded. Granulocytopenia was reported to be the dose-limiting
but, nevertheless, manageable toxicity.
The above results, together with the observation that the site at
which the taxanes bind tubulin differs from that of vinorelbine,
have prompted exploration of the potentially additive cytotoxic
effects of docetaxel and vinorelbine when used in combination in
women with advanced ovarian cancer.
Phase II combination data
The safety and efficacy of vinorelbine 25mgm
 2 on days 1 and 8
together with docetaxel 70mgm
 2 on day 8, every 3 weeks for up
to six cycles, was investigated in a Phase II study in women
(n¼46) with platinum-resistant, paclitaxel-pretreated recurrent
ovarian cancer (Aravantinos et al, 2002). Prophylactic G-CSF was
given on days 12 16. After a median of four cycles, the overall
response rate was 24%, three patients (6.5%) had complete
responses and eight (17.5%) had partial responses; 14 (30%)
patients had stable disease. With a median follow-up of 30 months,
median overall survival was 9 months, time to progression was 5.5
months, disease-free survival, 13 months and relapse-free survival,
6 months. Severe toxicities included granulocytopenia (35%),
leucopenia (31%) and febrile neutropenia (20%). Overall, efficacy
data and the manageable toxicity profile of the doublet combina-
tion docetaxel–vinorelbine indicated that further investigation is
warranted.
DOCETAXEL AND GEMCITABINE
Gemcitabine is an S-phase-specific antimetabolite with demon-
strated activity in a range of tumour types, particularly those
affecting the pancreas, lung and bladder (Beers and Berkow, 1999).
As with other treatments discussed in this review, differences in
mode of action give rise to the potential for enhanced cytotoxic
activity when gemcitabine is used in combination with other
chemotherapeutic agents; indeed, in vivo experiments in murine
tumours showed additive and supraadditive activities (chiefly
through enhancement of induced apoptosis) when docetaxel and
gemcitabine were combined in a variety of different sequences
(Mason et al, 2001). In addition, synergistic cytotoxicity has been
reported in a human cancer cell line after administration of
gemcitabine followed by docetaxel 96h later (Ishmael et al, 2001).
The activity of gemcitabine as monotherapy in advanced ovarian
cancer was shown in a study of 38 women, all of whom had
received prior platinum-based therapy and 27 of whom had also
received paclitaxel (Shapiro et al, 1996). Of 31 evaluable patients,
four (12.9%) showed a partial response and six (19.3%) women
had stable disease with a reduction of more than 50% in levels of
CA125 for at least 3 months. Uncomplicated neutropenia was the
main haematological toxicity; nonhaematological adverse effects
were mild and included fatigue, myalgia and rash.
Promising activity of paclitaxel plus gemcitabine in 21-day
(Iaffaioli et al, 2000) or 28-day (Roman et al, 2001) cycles has been
shown in patients with previously treated/platinum-resistant
advanced ovarian cancer (overall objective response rates of over
40%); in addition, a Phase I study has shown activity (including a
complete response in one patient with ovarian carcinoma) of
gemcitabine 500–800mgm
 2 on days 1, 8 and 15 plus docetaxel
60mgm
 2 on day 1 every 28 days in patients with a variety of
metastatic tumours (Ryan et al, 2000). A further study in 45
evaluable patients, with various tumour types, has shown good
activity of an alternating sequence of gemcitabine (800–
2500mgm
 2) in weeks 1, 3 and 5 plus docetaxel (30–55mgm
 2)
in weeks 2, 4 and 6, repeated every 8 weeks, with objective tumour
responses in two of three patients with ovarian cancer (Ishmael
et al, 2001).
In accordance with the above observations and the current
interest in sequential regimens involving gemcitabine, a novel
schedule consisting of four cycles of carboplatin monotherapy
followed by a combination of docetaxel (or paclitaxel) with
gemcitabine or CPT-11 either weekly or 3-weekly is currently being
assessed as first-line therapy in patients with advanced ovarian
cancer (Kaye, 2001b). The 3-weekly regimen appears to be more
promising based on the response and toxicity data (Vasey P et al,
2003).
TRIPLE CHEMOTHERAPY
The incorporation of novel drugs to which tumours are not
crossresistant into first-line chemotherapy offers the potential for
improved antitumour activity and survival in women with
advanced ovarian cancer. Options include the direct addition of
a third agent to a doublet, resulting in a three-drug combination,
or the administration of sequential regimens.
Benefits of adding an anthracycline
The addition of an anthracycline to dual therapy in patients with
ovarian cancer has been the focus of many studies and remains the
source of some controversy. Randomised trials in over 1200
patients have compared regimens containing the anthracycline
doxorubicin in addition to cyclophosphamide and cisplatin (CAP)
with cisplatin and cyclophosphamide alone, and have shown
nonsignificant trends only towards a survival advantage for CAP
(Conte et al, 1986; Bertelsen et al, 1987; Omura et al, 1989; GICOG,
1992). However, a pooled analysis of data from over 1700 patients
suggested a modest but significant improvement (hazard ratio
0.85; P¼0.003) in survival after the addition of doxorubicin to
platinum- or nonplatinum-based chemotherapy in advanced
ovarian cancer (A’Hern and Gore, 1995).
The combination of platinum agents with a taxane and an
anthracycline in advanced ovarian cancer has also been the subject
of discussion in the literature. Results from the first phase of a
study in which doxorubicin 50mgm
 2 was added to carboplatin
(to achieve an AUC 7mgml
 1min
 1) and paclitaxel 175mgm
 2 in
a 3-weekly cycle, with G-CSF support if needed, indicated activity
in patients who were ineligible for standard chemotherapy (Hill
et al, 1997). Of seven treated women, all five with evaluable
tumours achieved a response (one complete). Toxicity was
significant, however, with grade III–IV thrombocytopenia and
grade II–IV leucopenia in all patients; the regimen was therefore
concluded to be suitable for very fit patients only.
Results to date from a randomised Phase III study show no
significant benefit from the addition of the newer and less
cardiotoxic anthracycline epirubicin at a dose of 60mgm
 2 to
paclitaxel 175mgm
 2 plus carboplatin to AUC 5mgml
 1min
 1
every 3 weeks for the first-line treatment of stage IIb–IV ovarian
cancer, although a trend towards improved progression-free
survival was evident with epirubicin in 1121 evaluable patients
who received at least two cycles (du Bois et al, 2001). However, the
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myelotoxicity than dual therapy.
Most recently, the feasibility and safety of the addition of
epirubicin to a combination of docetaxel and carboplatin for first-
line therapy have been examined in a dose-finding study in 21
patients with stage Ic–IV disease (with stage Ic recruitment being
limited to patients with malignant cells in ascitic fluid or peritoneal
washings, or with preoperative capsular rupture or with surface
tumour) (O’Neill et al, 2002). The dose of docetaxel was fixed at
75mgm
 2, with carboplatin administered to achieve AUC 4–
5mgml
 1min
 1. Epirubicin was given at 50–60mgm
 2. Drugs
were given on day 1 of each 3-weekly cycle in cohorts 1, 2 and 4. In
cohort 3, epirubicin 50mgm
 2 was given on day 8. Patients
received up to six cycles of chemotherapy. At baseline, 73% of
patients had stage III–IV disease and 57% had undergone optimal
debulking.
Of 11 patients with radiologically evaluable disease, four showed
a complete response and three had disease stabilisation. In all, 16
patients were evaluable for CA 125, of whom 10 (62.5%) were
classified as responders. After 20 months of follow-up, median
progression-free survival was 12 months, with 62% 1-year survival.
As shown in Table 2, myelosuppression was the adverse effect of
chief concern, although this was manageable. At dose level 1, grade
IV neutropenia was reported in 83% of patients, but this was not
accompanied by sepsis in the majority (81%). Neurotoxicity was
shown not to be a significant problem with this regimen (Figure 2)
and there were no toxicity-related treatment withdrawals. It
was concluded that the combination was active, but that its
utility may be limited by the need for toxicity-induced dose
reductions (necessary in 52% of patients in this study). It
was also suggested that future studies should examine the role of
scheduling in maximising activity and patient acceptability of
these agents.
Sequential therapy with epirubicin
Results are emerging from the French Oncology Multidisciplinary
Research Group’s (GERCOR) Phase II trial of repeated sequential
docetaxel, cisplatin and epirubicin as first-line therapy in 33
evaluable patients with suboptimally or optimally debulked stage
IIb–IV ovarian cancer (Molitor et al, 2000). Docetaxel 85mgm
 2
on day 1 was followed by cisplatin 75mgm
 2 on day 2 and
epirubicin 60mgm
 2 on day 3. The treatment was repeated every 3
weeks for up to six cycles. Among the 33 patients evaluable to date,
second-look surgery has revealed responses in 79% of patients
(17% complete), with median progression-free survival of 17
months. Major toxicities were haematological (febrile neutropenia
in 11% of cycles) despite the use of G-CSF in 65% of cycles, but
peripheral neuropathy was uncommon (Figure 3). As response and
progression-free survival rates were similar to those reported in
GERCOR trials of dual chemotherapy, two-drug treatment
followed by consolidation therapy with a third agent was suggested
as a feasible approach.
Future options with three-drug regimens
The results obtained with triple-drug combinations to date do not
allow definitive conclusions to be drawn with respect to the overall
clinical benefit of the addition of a third drug to dual-agent
chemotherapy. Exploring different drug sequences with the agents
Table 2 Grade III–IV haematological toxicities with 3-weekly triple chemotherapy with docetaxel plus carboplatin plus epirubicin for up to six cycles
(O’Neill et al, 2002)
Neutropenia (% of patients) Leucopenia (% of patients) Thrombocytopenia (% of patients) Anaemia (% of patients)
Cohort Grade III Grade IV Grade III Grade IV Grade III Grade IV Grade III Grade IV
1( n¼6)
a 17 83 17 50 0 0 17 0
2( n¼6)
b 0 100 0 100 17 33 17 0
3( n¼6)
c 33 67 83 17 17 0 33 0
4( n¼3)
d 0 100 0 67 0 0 0 0
aDocetaxel 75mgm
 2+carboplatin to AUC 5mgm
 1 min+epirubicin 50mgm
 2.
bDocetaxel 75mgm
 2+carboplatin to AUC 5mgm
 1 min+epirubicin 60mgm
 2.
cDocetaxel 75mgm
 2+carboplatin to AUC 5mgm
 1 min+epirubicin 50mgm
 2 (day 8),
dDocetaxel 75mgm
 2+carboplatin to AUC 4mgm
 1 min+epirubicin 50mgm
 2.
All drugs were given on day 1 of each cycle unless stated otherwise.
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Figure 2 Major nonhaematological toxicities among 21 patients
receiving triple combination therapy with docetaxel, carboplatin and
epirubicin every 3 weeks for up to six cycles (O’Neill et al, 2002). All
toxicities were grade III, apart from tiredness/lethargy and sensory
neuropathy (grade II).
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Figure 3 Grade III–IV toxicities in 33 patients with advanced ovarian
cancer being treated with first-line sequential therapy with docetaxel
85mgm
 2 (day 1), cisplatin 75mgm
 2 (day 2) and epirubicin 60mgm
 2
(day 3) every 3 weeks for up to six cycles (Molitor et al, 2000).
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tried to good effect in patients with breast cancer undergoing
treatment with adjuvant chemotherapy (Bonadonna et al, 1995;
Henderson et al, 1998) (for a further review, see article 4, Vasey P,
2003).
Further tolerability improvements may be achieved through the
use of liposomally encapsulated doxorubicin — a formulation that
may cause less myelosuppression and cardiotoxicity than conven-
tional doxorubicin — as a taxane–platinum partner. This
approach has been evaluated in two recent Phase I studies in
patients with various tumour types treated with liposomal
doxorubicin in combination with paclitaxel and cisplatin or
carboplatin (Jacobs et al, 2000; Rose et al, 2000). Early data
indicate activity and acceptable levels of toxicity, but more
research will be required to clarify further the potential role of
such treatment. The combination of liposomal doxorubicin with
docetaxel-based chemotherapy remains to be investigated.
CONCLUSIONS
As can be seen from the findings discussed in this review, recent
and ongoing work has shown considerable promise of a number of
novel combination chemotherapy regimens involving docetaxel in
patients with advanced ovarian cancer. In particular, Phase I and II
studies investigating docetaxel in combination with the camp-
tothecin topoisomerase inhibitors CPT-11 and topotecan as
second-line therapy have been successful; these dual therapies
merit further investigation. Preliminary results are also available
suggesting good activity of combinations of docetaxel with
gemcitabine; studies assessing chemotherapy with these two agents
are ongoing.
Studies of triple chemotherapy have produced inconsistent
results. However, there are indications of the clinical benefit of
adding an anthracycline to a platinum agent plus a taxane, with
encouraging findings in a recent dose-finding study of docetaxel,
carboplatin and epirubicin. It is possible that manipulation of drug
sequences may be of value when this type of combination is used
and, accordingly, the French GERCOR group is undertaking a
study of sequential docetaxel, cisplatin and epirubicin, the final
results of which are awaited.
In conclusion, although the results discussed are largely
preliminary or from Phase II studies, they indicate the clear
possibility of further progress in the chemotherapy of advanced
ovarian cancer. As the majority of patients with this disease
still experience progression after treatment, further trials
involving docetaxel in combination with other agents should be
encouraged.
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